---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027201"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2026-06-04T12:00:40+00:00"
generated_at: "2026-06-04T12:06:34.218565+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IMUNON secures up to $10M through preferred stock and secured notes for Phase 3 trial

## Summary
- Gross proceeds of $10M from 250 Series A Preferred shares ($2.5M) and secured promissory notes ($7.72M total).
- Notes mature in 18 months; A-1 Note at 8% interest, B Note at 5%; secured by assets except IP.
- $5M placed in cash collateral; remaining $5M for general corporate purposes including Phase 3 OVATION 3 trial.
- Preferred stock is non-convertible, non-voting, 8% annual return; redeemable at 110% of liquidation amount.
- Financing structured as non-dilutive with no warrants; management highlights shareholder-friendly terms.

## SEC filing metadata
- accession: 0001493152-26-027201
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2026-06-04T12:00:40+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027201
- JSON: https://secwatch.observer/filing/0001493152-26-027201.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027201.txt

## Key facts
- Debt Financings
  Imunon, Inc. incurred debt of $5,000,000 with Streeterville Capital, LLC at 5% per annum maturing 18 months following the Closing Date.
  - Principal: $5,000,000
  - Counterparty: Streeterville Capital, LLC
  - Rate: 5% per annum
  - Maturity: 18 months following the Closing Date
  - Event: incurrence
  source text: (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”). The transactions contemplated by the Securities Purchase Agreement (collectively, the “ Transaction ”) closed on
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm
- Debt Financings
  Imunon, Inc. incurred debt of $2,720,000 with Streeterville Capital, LLC at 8% per annum maturing 18 months following the Closing Date.
  - Principal: $2,720,000
  - Counterparty: Streeterville Capital, LLC
  - Rate: 8% per annum
  - Maturity: 18 months following the Closing Date
  - Event: incurrence
  source text: (the “ Series A Preferred Stock ”), at a price of $10,000 per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”). The
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm
- Governance Changes
  Imunon, Inc.: Filed a Certificate of Designation for Series A Preferred Stock designating 400 shares (effective 2026-06-01).
  - Change: charter amendment
  - Effective: 2026-06-01
  source text: On June 1, 2026, the Company filed a certificate of designation of preferences and rights (the “ Certificate of Designation ”) of the Series A Preferred Stock with the Secretary of State of the State of Delaware, designating 400 shares of Series A Preferred Stock, which became effective upon filing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm
- Material Agreements
  Imunon, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh (effective 2026-06-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Streeterville Capital, LLC
  - Value: Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh
  - Effective: 2026-06-02
  source text: On June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares (the “ Preferred Shares ”) of the Company’s Series A Preferred Stock, par value $0.01 per share (the “ Series A Preferred Stock ”), at a price of $10,000 per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.